



(51) International Patent Classification:

C12N 9/64 (2006.01) C07K 1/22 (2006.01)

(21) International Application Number:

PCT/US2017/038169

(22) International Filing Date:

19 June 2017 (19.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/351,841 17 June 2016 (17.06.2016) US

(71) Applicant: **PORTOLA PHARMACEUTICALS, INC.**
[US/US]; 270 E. Grand Ave., Suite 22, South San Francisco,
California 94080 (US).

(72) Inventors: **KARBARZ, Mark**; c/o Portola Pharmaceuticals,
Inc., 270 E. Grand Ave., Suite 22, South San Francisco,
California 94080 (US). **CONLEY, Pamela B.**; c/o
Portola Pharmaceuticals, Inc., 270 E. Grand Ave., Suite 22,
South San Francisco, California 94080 (US). **LU, Genmin**;
c/o Portola Pharmaceuticals, Inc., 270 E. Grand Ave., Suite
22, South San Francisco, California 94080 (US).

(74) Agent: **NIE, Alex Y.** et al.; SHEPPARD MULLIN
RICHTER & HAMPTON LLP, 379 Lytton Avenue, Palo
Alto, California 94301-1479 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: PREPARATION OF FACTOR XA DERIVATIVES

(57) Abstract: The present disclosure provides methods for manufacturing a tXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.

